ENGOT-OV16/NOVA non-gBRCA | niraparib (300 mg) once daily (n=138) vs. placebo (n=65) | patients with platinum-sensitive, recurrent ovarian cancer | double-blind Parallel groups Sample size: 138/65 Primary endpoint: progression-free survival FU duration: |
ENGOT-OV16/NOVA gBRCA, 2017 | niraparib (300 mg) once daily as maintenance treatment (n=138) vs. placebo
(n=65) | patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation
| double-blind Parallel groups Sample size: 138/65 Primary endpoint: progression-free survival FU duration: |